Sign in
Not yet taking people in New ZealandNo phase

Testing a new face mask for home breathing support in COPD and obesity hypoventilation

Tests a new mask for home breathing machines in adults with COPD or obesity hypoventilation.

Key facts

Who runs it
Fisher and Paykel Healthcare
Where
Auckland, New ZealandSee the site
Trial code
Registry title
The Effect of Mask Design on Ventilation Parameters in COPD and OHS Patients on Long-term Home Non-invasive Ventilation. An Experimental Study.
Status
Not yet recruiting
People taking part
20 people, planned
Started
May 2025
Planned end
Apr 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Investigational Mask
  • Conventional mask
Record updated
15 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults on night-time non-invasive ventilation (NIV) for COPD or obesity hypoventilation syndrome. It tests whether a new mask improves breathing.

Age
Over 18 years (minimum age 18 Years)
Sex
All sexes can join.
Disease stage
COPD or obesity hypoventilation syndrome (OHS) treated with night-time NIV.
Earlier treatment
Must have been prescribed night-time NIV for COPD or OHS.

Main reasons for not taking part

  • Uncontrolled sleep apnea (AHI over 15 events/hour off personal NIV device data)
  • Prescribed IPAP above 25 cmH2O
  • Allergic to the adhesive of the sensors
  • Self-reported cold or flu symptoms

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age over 18 years
  • Prescribed nocturnal NIV for COPD or OHS
  • Able to complete an overnight sleep study
  • Comfortable to sleep on a standard double bed
  • Capacity to complete informed consent

Who cannot take part

  • Allergic to adhesive of the sensors
  • Uncontrolled sleep apnea (Apnea-hypopnea index (AHI) over 15 events/hour off personal NIV device data)
  • Prescribed IPAP above 25 cmH2O
  • Self-reported cold/flu symptoms

Where in New Zealand

  • Fisher and Paykel Healthcare Sleep LaboratoryAuckland, New ZealandContact: Jessica FogarinNot yet recruiting

About the trial

What the trial wants to find out

Chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome (OHS) are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV) delivers positive pressures via an interface such as a face mask and has been shown to improve breathing and reduce symptoms in patients with these conditions. Regular use of NIV can lead to better symptom management, improved quality of life, and reduced use of healthcare resources. However, poor performance of the NIV mask and poor comfort can make NIV therapy harder to tolerate. This study will assess if a new mask helps to improve the breathing of people on NIV and normalize blood gases.

The 2 groups in the trial

  • Noninvasive ventilation (CPAP or bilevel) with the investigational maskTreatment being tested

    Treatment: Investigational Mask

  • Noninvasive ventilation (CPAP or bilevel) with the conventional maskExisting treatment, for comparison

    Treatment: Conventional mask

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Mask Design on Ventilation Parameters in COPD and OHS Patients on Long-term Home Non-invasive Ventilation. An Experimental Study.
Plain-language title
Testing a new face mask for home breathing support in COPD and obesity hypoventilationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 May 2025